INTRODUCTION
The coronavirus disease-2019 (COVID-19) pandemic has unique implications for the growing cohort of survivors of childhood cancer and hematopoietic cell transplantation (HCT) for non-malignant hematologic/immune disorders,1,2 referred to herein as “survivors.” Investigators have postulated that history of underlying immune dysfunction and/or organ injury due to prior therapeutic exposures increase survivors’ risk of contracting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and/or increased severity of COVID-19.3,4,5 Using the Childhood Cancer Survivor Study (CCSS) cohort, Perkins et. al previously found an increased incidence of overall infections and a higher risk of infection-related mortality among survivors of childhood cancer as compared to unaffected siblings for at least 35 years after therapy.6 Whether these infectious risk findings can be applied to the COVID-19 pandemic and inform guidelines for childhood cancer survivors as they return to school or work is unknown.5 In an effort to fill this gap, we assessed reported COVID-19 symptoms, exposures, and/or hospitalization, as well as SARS-CoV-2 IgG status, in a cohort of pediatric survivors presenting for routine long-term follow-up (LTFU) either in-person or virtually in the early months of the COVID-19 pandemic in New York City, one of the original epicenters of the pandemic.